Liminatus Pharma (LIMN) Stock Chart & Stock Price History $5.42 -0.05 (-0.91%) As of 11:08 AM Eastern Add Compare Share Share Chart Stock AnalysisChartCompetitorsFDA EventsSEC FilingsTrendsBuy This Stock Liminatus Pharma Stock Price Performance The Liminatus Pharma (LIMN) stock chart highlights key performance trends across multiple timeframes. As of the latest close, Liminatus Pharma traded at $5.47 with a market cap of $142.30 million and volume of 379,702 shares. Receive LIMN Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Liminatus Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-18.50% LIMN Stock Chart for Friday, July, 18, 2025 LIMN Chart by TradingView Liminatus Pharma Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/17/2025$5.40$5.47+1.30%$6.06$5.30379,702 shs$142.30 million07/16/2025$5.59$5.40-3.40%$5.70$5.25212,589 shs$140.45 million07/15/2025$6.33$5.59-11.69%$6.37$5.52141,707 shs$145.42 million07/14/2025$6.65$6.33-4.81%$6.90$6.00138,957 shs$164.68 million07/11/2025$7.20$6.65-7.64%$7.26$6.33180,160 shs$173 million07/10/2025$5.22$7.20+37.93%$7.45$5.82822,339 shs$187.27 million07/09/2025$6.28$5.22-16.88%$6.36$5.05369,649 shs$135.77 million07/08/2025$6.93$6.28-9.38%$8.10$5.92384,740 shs$163.37 million07/07/2025$9.02$6.93-23.17%$9.00$6.80218,015 shs$180.25 million07/04/2025$9.02$9.02$10.20$8.74196,150 shs$234.66 million Get the Latest News and Ratings for LIMN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Liminatus Pharma and its competitors with MarketBeat's FREE daily newsletter. 07/03/2025$8.81$9.02+2.38%$10.20$8.74196,150 shs$234.61 million07/02/2025$10.35$8.81-14.88%$10.75$8.80283,496 shs$229.15 million07/01/2025$11.15$10.35-7.17%$11.90$10.12113,652 shs$269.20 million06/30/2025$9.48$11.15+17.62%$12.90$10.67505,433 shs$290.01 million06/27/2025$16.60$9.48-42.89%$17.55$9.00668,535 shs$246.58 million06/26/2025$23.98$16.60-30.78%$22.71$16.50197,392 shs$431.77 million06/25/2025N/A$23.98$33.66$19.21626,975 shs$623.84 million Related Companies Rapport Therapeutics Stock Chart Oruka Therapeutics Stock Chart Arvinas Stock Chart Kura Oncology Stock Chart Valneva Stock Chart Taysha Gene Therapies Stock Chart Prime Medicine Stock Chart Precigen Stock Chart atai Life Sciences Stock Chart Bicycle Therapeutics Stock Chart Receive LIMN Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Liminatus Pharma and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:LIMN) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liminatus Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Liminatus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.